Sequana Medical
94 articles about Sequana Medical
-
Sequana Medical Announces 2020 Full Year Results and 2021 Outlook
3/17/2021
Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces its financial results for the year ended 31 December 2020, and provides a business update and an outlook for the remainder of 2021.
-
Sequana Medical Notice of 2020 Full Year Results and Business Update
3/10/2021
Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021.
-
Sequana Medical's New Share Capital Amount and New Number of Shares
2/16/2021
Sequana Medical NV announces, in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of the capital increase that was announced on 9 February and completed on 15 February 2021 by means of a private placement through an accelerated bookbuilding procedure...
-
Sequana Medical announces February-March 2021 Investor Conference Schedule
2/15/2021
Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that its management team will participate in the following upcoming virtual investor conferences.
-
Sequana Medical Announces Granting of Key alfapump DSR® Patents in U.S. and Europe
2/4/2021
Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces the granting of key patents for the alfapump DSR programme in the U.S. and European Union.
-
Sequana Medical Announces January 2021 Investor Conference Schedule
12/17/2020
Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference.
-
Sequana Medical to Host KOL Event on “The Challenge of Diuretic Resistance in the Management of Heart Failure Patients and the Potential for alfapump® DSR therapy”
12/7/2020
Sequana Medical NV announces that it will hold a key opinion leader event on the challenge of diuretic resistance in the management of heart failure patients and the potential for alfapump® DSR therapy, on Friday 11 December 2020 at 03:00 pm CET / 09:00 am EST.
-
Sequana Medical Announces Positive Interim Data From North American Pivotal alfapump® Study (POSEIDON)
11/19/2020
Results from first 13 patients in Roll-In Cohort showed over 90% reduction in mean frequency of therapeutic paracentesis versusbaseline
-
Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference
11/12/2020
Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies 2020 Virtual London Healthcare Conference taking place from 17 to 19 November 2020.
-
Sequana Medical Announces Strong Interim Results From RED DESERT alfapump® DSR Study and Provides Business Update
10/22/2020
Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces positive interim results from the first five patients enrolled in the RED DESERT study, evaluating repeated dose treatment of alfapump DSR in diuretic-resistant heart failure patients.
-
Sequana Medical Appoints Two Additional Experts as Heart Failure Scientific Advisors
10/15/2020
Dr.Felker and Dr. Udelson join current advisors to support the development ofalfapump® DSR for the management of fluid overload in patients with heart failure
-
Sequana Medical announces September 2020 Investor Conference Schedule
9/9/2020
Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces that it will participate in two virtual investor events in September 2020.
-
Sequana Medical announces H1 2020 results and provides business update
9/3/2020
Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces its business highlights and financial results for the six-month period ending 30 June 2020 and its outlook for the remainder of the year and into 2021.
-
Sequana Medical Notice of 2020 Half Year Results and Business Update
8/27/2020
Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, will announce its results for the half year ended 30 June 2020 on Thursday, 3 September 2020.
-
Sequana Medical Announces €7.3 Million Debt Financing and Provides Clinical Update
7/28/2020
Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces it has secured a €7.3 million debt financing through subordinated loan agreements, of which €1.4 million will be convertible for new shares of the Company.
-
Sequana Medical Announces That the Results of the alfapump® MOSAIC Study Have Been Published in Liver Transplantation
6/16/2020
North American feasibility study demonstrated the utility, safety and efficacy of the alfapump in the management of patients with recurrent and refractory ascites
-
Sequana Medical Announces the Appointment of Dr. Oliver Gödje as Chief Medical Officer
5/4/2020
Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer, with immediate effect.
-
Sequana Medical Announces 2019 Full Year Results and 2020 Outlook
3/19/2020
Sequana Medical NV announces its financial results for the year ended 31 December 2019, and provides a business update and an outlook for the remainder of 2020.
-
Clinical Catch-Up: January 6-10, 2020
1/13/2020
The first full business week of the new year began with plenty of clinical trial news. Here’s a look. -
Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients
1/7/2020
Sequana Medical NV announces that the first patient has been enrolled in the first-in-human repeated dose study of alfapump DSR for the treatment of diuretic-resistant heart failure patients.